Physician profile
John M Gilbert
NPI 1588650667
$420,931.73
in general payments reported to CMS, 2019-2025
45 companies · $79K in 2025
The $79K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $49K · 2021: $90K · 2022: $58K · 2023: $57K · 2024: $39K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $108K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $32K · Travel and Lodging: $12K · Consulting Fee: $12K · Food and Beverage: $10K · Gift: $59.40 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $108,020.38 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $31,812.50 |
| Travel and Lodging | $12,401.65 |
| Consulting Fee | $11,625.00 |
| Food and Beverage | $10,164.07 |
| Gift | $59.40 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $150,252.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $121,410.33 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $83,481.08 | 2019-2025 | Lyumjev, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $31,171.17 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $12,603.52 | 2019-2025 | |
| Amgen INC. | $10,765.22 | 2019-2025 | Tepezza, Evenity, Prolia |
| Abbvie INC. | $5,384.23 | 2019-2025 | |
| Dexcom, INC. | $1,408.66 | 2019-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $561.00 | 2019-2025 | Jardiance |
| Corcept Therapeutics | $426.92 | 2021-2025 | Korlym |
| Medtronic, INC. | $382.56 | 2021-2024 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Recordati_rare_diseases_inc. | $294.05 | 2024-2025 | Isturisa, Signifor Lar |
| Medtronic Minimed, INC. | $289.51 | 2019 | |
| Horizon Therapeutics Plc | $236.17 | 2020-2023 | Tepezza |
| Tandem Diabetes Care, INC. | $213.29 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $192.56 | 2021-2025 | Afrezza |
| Radius Health, INC. | $183.59 | 2019-2024 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $182.25 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $164.97 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $155.10 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Lifescan, INC. | $138.71 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $135.17 | 2023-2025 | |
| Insulet Corporation | $134.09 | 2023-2024 | Omnipod |
| Kyowa Kirin, INC. | $103.60 | 2023-2025 | Crysvita |
| Ibsa Pharma INC. | $78.15 | 2019-2025 | Tirosint, Licart, Tirosint |
| Grt US Holding, INC. | $49.86 | 2021 | |
| Sequel Med Tech, LLC | $42.40 | 2025 | Twiist |
| Ultragenyx Pharmaceutical INC. | $41.54 | 2021 | |
| Amarin Pharma, INC. | $40.40 | 2019-2021 | |
| Becton, Dickinson and Company | $40.22 | 2022 | |
| Alexion Pharmaceuticals, INC. | $38.64 | 2019-2023 | Strensiq |
| Embecta Corp. | $37.53 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Cequr Corporation | $34.08 | 2022-2023 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $31.84 | 2019-2021 | |
| Averitas Pharma INC. | $27.43 | 2023 | Qutenza |
| Ascensia Diabetes Care US INC. | $24.81 | 2023 | |
| Verity Pharmaceuticals INC. | $24.17 | 2025 | Tlando |
| Shield Therapeutics INC | $24.04 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $23.98 | 2019 | |
| Madrigal Pharmaceuticals | $23.64 | 2025 | Rezdiffra |
| Amryt Pharma Holdings Ltd | $21.98 | 2023 | Mycapssa |
| Bigfoot Biomedical INC | $21.39 | 2022 | |
| Aytu Biopharma, INC. | $18.13 | 2019 | |
| Pfizer INC. | $17.57 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.